Patents by Inventor Michel Rivier

Michel Rivier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7968560
    Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: June 28, 2011
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Etienne Thoreau, Michel Rivier, Jerome Aubert, Laurent Chantalat, Johannes Voegel
  • Publication number: 20110150773
    Abstract: An in vitro method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of acetyl-coenzyme A acyltransferase 1 (ACAA1) or of acetyl-coenzyme A acyltransferase 2 (ACAA2), and also utilizes modulators of the expression or of the activity of either of these enzymes, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.
    Type: Application
    Filed: May 7, 2009
    Publication date: June 23, 2011
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jérôme Aubert, Michel Rivier, Johannes Voegel
  • Publication number: 20110150772
    Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of carnitine octanoyltransferase (CROT), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.
    Type: Application
    Filed: May 7, 2009
    Publication date: June 23, 2011
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Michel Rivier
  • Publication number: 20110150774
    Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the carboxylesterase 1 (CES1) and/or carboxylesterase 3 (CES3) proteins.
    Type: Application
    Filed: May 7, 2009
    Publication date: June 23, 2011
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Michel Rivier, Séverine Corvaisier, André Jomard
  • Patent number: 7944280
    Abstract: A circuit for providing a bandgap voltage. The circuit includes a classic bandgap reference voltage generation circuit including first end second serially connected transistors acting as a current mirror to another portion of the classical bandgap reference circuit and being coupled between a supply voltage Vdd and an output resistor. The circuit also includes a current trimming circuit coupled in parallel with the classical bandgap reference generation circuit including a fixed element portion including a plurality of transistors and a switch portion including a plurality of switches. Each of the plurality of transistors is coupled to the supply voltage Vdd and to a one of the plurality of switches and each switch includes a fuse.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: May 17, 2011
    Assignee: International Business Machines Corporation
    Inventors: Bertrand Gabillard, Philippe Girard, Michel Rivier
  • Patent number: 7807669
    Abstract: Novel biaromatic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: October 5, 2010
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Claire Bouix-Peter, Michel Rivier, Pascal Collette, Andre Jomard
  • Publication number: 20100247468
    Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
    Type: Application
    Filed: September 21, 2009
    Publication date: September 30, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence Clary, Etienne Thoreau, Michel Rivier, Jerome Aubert, Laurent Chantalat, Johannes Voegel
  • Publication number: 20100168231
    Abstract: The use of an enzyme as a research tool for acne, by identifying a compound for the treatment of acne and/or any disorder associated with cutaneous hyperseborrhoea.
    Type: Application
    Filed: January 5, 2010
    Publication date: July 1, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurent Lamy, Michel Rivier, Gérard Feraille
  • Publication number: 20100099689
    Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
    Type: Application
    Filed: September 18, 2009
    Publication date: April 22, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence CLARY, Etienne Thoreau, Michel Rivier, Jerome Aubert, Laurent Chantalat, Johannes Voegel
  • Publication number: 20100035988
    Abstract: Novel biaromatic compounds having the following structural formula (I): are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, in particular in dermatology as well as in the fields of cardiovascular diseases, immune diseases and/or diseases related to the metabolism of lipids, or, alternatively, into cosmetic compositions.
    Type: Application
    Filed: October 9, 2009
    Publication date: February 11, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jerome Aubert, Laurence Clary, Pascale Mauvais, Michel Rivier, Etienne Thoreau, Jean-Guy Boiteau
  • Publication number: 20100028879
    Abstract: An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of hydroxysteroid (17-beta) dehydrogenase type 7, and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or in vitro prognosis of these pathologies are also described.
    Type: Application
    Filed: January 21, 2009
    Publication date: February 4, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Fernand Labrie, Michel Rivier, Van Luu-The, Ezequiel L. Calvo, Jerome Aubert, Sophie Deret, Johannes Voegel
  • Publication number: 20100028878
    Abstract: An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of UDP-glucose ceramide glucosyltransferase (UGCG), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperkeratinization; methods for the in vitro diagnosis or prognosis of these pathologies are also described.
    Type: Application
    Filed: January 21, 2009
    Publication date: February 4, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Fernand Labrie, Michel Rivier, Van Luu-The, Ezquiel L. Calvo, Irina Safonova, Isabelle Carlavan
  • Publication number: 20090298074
    Abstract: An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of ELOVL5 and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described.
    Type: Application
    Filed: January 21, 2009
    Publication date: December 3, 2009
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Fernand Labrie, Mohamed El-Alfy, Van Luu-The, Ezequiel L. Calvo, Pascal Collette, Sophie Deret, Michel Rivier
  • Patent number: 7626054
    Abstract: Novel biaromatic compounds having the following structural formula (I): are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, in particular in dermatology as well as in the fields of cardiovascular diseases, immune diseases and/or diseases related to the metabolism of lipids, or, alternatively, into cosmetic compositions.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: December 1, 2009
    Assignee: Galderma Research & Development
    Inventors: Jerome Aubert, Laurence Clary, Pascale Mauvais, Michel Rivier, Etienne Thoreau, Jean-Guy Boiteau
  • Patent number: 7625914
    Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: December 1, 2009
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Etienne Thoreau, Michel Rivier, Jerome Aubert, Laurent Chantalat, Johannes Voegel
  • Publication number: 20090289697
    Abstract: A circuit for providing a bandgap voltage. The circuit includes a classic bandgap reference voltage generation circuit including first end second serially connected transistors acting as a current mirror to another portion of the classical bandgap reference circuit and being coupled between a supply voltage Vdd and an output resistor. The circuit also includes a current trimming circuit coupled in parallel with the classical bandgap reference generation circuit including a fixed element portion including a plurality of transistors and a switch portion including a plurality of switches. Each of the plurality of transistors is coupled to the supply voltage Vdd and to a one of the plurality of switches and each switch includes a fuse.
    Type: Application
    Filed: August 26, 2008
    Publication date: November 26, 2009
    Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Bertrand Gabillard, Philippe Girard, Michel Rivier
  • Publication number: 20090258356
    Abstract: An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the peroxisome membrane transporter 1 comprising a type 3 ATP-binding site of the sub-family D (ABCD3), and the use of modulators of the expression or activity of this transporter for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described.
    Type: Application
    Filed: January 21, 2009
    Publication date: October 15, 2009
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Fernand Labrie, Mohamed El-Alfy, Ezequiel L. Calvo, Isabelle Carlavan, Pascal Collette, Sophie Deret, Michel Rivier
  • Patent number: 7582663
    Abstract: Novel biaromatic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: September 1, 2009
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Claire Bouix-Peter, Michel Rivier, Pascal Collette, Andre Jomard
  • Publication number: 20090062340
    Abstract: Novel biaromatic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.
    Type: Application
    Filed: November 6, 2008
    Publication date: March 5, 2009
    Applicant: Galderma Research & Development
    Inventors: LAURENCE CLARY, CLAIRE BOUIX-PETER, MICHEL RIVIER, PASCAL COLLETTE, ANDRE JOMARD
  • Publication number: 20090012129
    Abstract: Novel biaromatic compounds that modulate peroxisome proliferator-activator receptors, known as PPAR, having the formula (I): are formulated into pharmaceutical compositions useful in human or veterinary medicine, or alternatively, in cosmetic compositions.
    Type: Application
    Filed: April 28, 2008
    Publication date: January 8, 2009
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Guy Boiteau, Laurence Clary, Laurent Chantalat, Michel Rivier